User:Mr. Ibrahem/Empagliflozin

Empagliflozin, sold under the brand name Jardiance among others, is a medication used together with diet and exercise to treat type 2 diabetes. It is less preferred than metformin and sulfonylureas. It may be used together with other medications such as metformin or insulin. It is not recommended for type 1 diabetes. It is taken by mouth.

Common side effects include urinary tract infections, fungal infections of the groin, and joint pains. Rarer but more serious side effects include a skin infection of the groin called Fournier's gangrene and a form of diabetic ketoacidosis with normal blood sugar levels. Use in pregnancy and breastfeeding is not recommended. Use is not recommended in those with significant kidney disease, though it may help slow the progression of mild kidney problems. Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and works by increasing sugar lost in the urine.

Empagliflozin was approved for medical use in the US and in the European Union in 2014. It is on the World Health Organization's List of Essential Medicines. A month supply in the UK costs the NHS about GB£36.59. In the US, the wholesale cost of this amount is about US$442. In 2017, it was the 228th most commonly prescribed medication in the United States, with more than two million prescriptions.